Pharma & Healthcare
Global Human Vaccines Administered Orally Market Insights, Forecast to 2030
- Mar 11, 25
- ID: 4297
- Pages: 110
- Figures: 144
- Views: 22
Oral vaccines are safe and easy to administer and convenient for all ages. They have been successfully developed to protect from many infectious diseases acquired through oral transmission. Oral delivery of vaccines represents the most attractive mode of administration over other routes of delivery due to the fact that the oral vaccination is noninvasive, safe and simple to execute, showing good patient compliance and clinical practicality.
The global Human Vaccines Administered Orally market is projected to grow from US$ 1936 million in 2024 to US$ 2746.3 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.0% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Human Vaccines Administered Orally, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Human Vaccines Administered Orally, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Human Vaccines Administered Orally, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Human Vaccines Administered Orally sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Human Vaccines Administered Orally market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Human Vaccines Administered Orally sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Segment by Application
Public
Private
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Human Vaccines Administered Orally in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Human Vaccines Administered Orally manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Vaccines Administered Orally sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
The global Human Vaccines Administered Orally market is projected to grow from US$ 1936 million in 2024 to US$ 2746.3 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.0% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Human Vaccines Administered Orally, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Human Vaccines Administered Orally, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Human Vaccines Administered Orally, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Human Vaccines Administered Orally sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Human Vaccines Administered Orally market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Human Vaccines Administered Orally sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Segment by Application
Public
Private
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Human Vaccines Administered Orally in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Human Vaccines Administered Orally manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Vaccines Administered Orally sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Human Vaccines Administered Orally Product Introduction
1.2 Market by Type
1.2.1 Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Rotavirus Vaccine
1.2.3 Cholera Vaccine
1.2.4 Oral Polio Vaccine
1.3 Market by Application
1.3.1 Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Public
1.3.3 Private
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Vaccines Administered Orally Sales Estimates and Forecasts 2019-2030
2.2 Global Human Vaccines Administered Orally Revenue by Region
2.2.1 Global Human Vaccines Administered Orally Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Human Vaccines Administered Orally Revenue by Region (2019-2024)
2.2.3 Global Human Vaccines Administered Orally Revenue by Region (2025-2030)
2.2.4 Global Human Vaccines Administered Orally Revenue Market Share by Region (2019-2030)
2.3 Global Human Vaccines Administered Orally Sales Estimates and Forecasts 2019-2030
2.4 Global Human Vaccines Administered Orally Sales by Region
2.4.1 Global Human Vaccines Administered Orally Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Human Vaccines Administered Orally Sales by Region (2019-2024)
2.4.3 Global Human Vaccines Administered Orally Sales by Region (2025-2030)
2.4.4 Global Human Vaccines Administered Orally Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Human Vaccines Administered Orally Sales by Manufacturers
3.1.1 Global Human Vaccines Administered Orally Sales by Manufacturers (2019-2024)
3.1.2 Global Human Vaccines Administered Orally Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Vaccines Administered Orally in 2023
3.2 Global Human Vaccines Administered Orally Revenue by Manufacturers
3.2.1 Global Human Vaccines Administered Orally Revenue by Manufacturers (2019-2024)
3.2.2 Global Human Vaccines Administered Orally Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Human Vaccines Administered Orally Revenue in 2023
3.3 Global Key Players of Human Vaccines Administered Orally, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Human Vaccines Administered Orally Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Human Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Human Vaccines Administered Orally, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Human Vaccines Administered Orally, Product Offered and Application
3.8 Global Key Manufacturers of Human Vaccines Administered Orally, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Human Vaccines Administered Orally Sales by Type
4.1.1 Global Human Vaccines Administered Orally Historical Sales by Type (2019-2024)
4.1.2 Global Human Vaccines Administered Orally Forecasted Sales by Type (2025-2030)
4.1.3 Global Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
4.2 Global Human Vaccines Administered Orally Revenue by Type
4.2.1 Global Human Vaccines Administered Orally Historical Revenue by Type (2019-2024)
4.2.2 Global Human Vaccines Administered Orally Forecasted Revenue by Type (2025-2030)
4.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
4.3 Global Human Vaccines Administered Orally Price by Type
4.3.1 Global Human Vaccines Administered Orally Price by Type (2019-2024)
4.3.2 Global Human Vaccines Administered Orally Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Human Vaccines Administered Orally Sales by Application
5.1.1 Global Human Vaccines Administered Orally Historical Sales by Application (2019-2024)
5.1.2 Global Human Vaccines Administered Orally Forecasted Sales by Application (2025-2030)
5.1.3 Global Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
5.2 Global Human Vaccines Administered Orally Revenue by Application
5.2.1 Global Human Vaccines Administered Orally Historical Revenue by Application (2019-2024)
5.2.2 Global Human Vaccines Administered Orally Forecasted Revenue by Application (2025-2030)
5.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
5.3 Global Human Vaccines Administered Orally Price by Application
5.3.1 Global Human Vaccines Administered Orally Price by Application (2019-2024)
5.3.2 Global Human Vaccines Administered Orally Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Human Vaccines Administered Orally Market Size by Type
6.1.1 US & Canada Human Vaccines Administered Orally Sales by Type (2019-2030)
6.1.2 US & Canada Human Vaccines Administered Orally Revenue by Type (2019-2030)
6.2 US & Canada Human Vaccines Administered Orally Market Size by Application
6.2.1 US & Canada Human Vaccines Administered Orally Sales by Application (2019-2030)
6.2.2 US & Canada Human Vaccines Administered Orally Revenue by Application (2019-2030)
6.3 US & Canada Human Vaccines Administered Orally Market Size by Country
6.3.1 US & Canada Human Vaccines Administered Orally Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Human Vaccines Administered Orally Sales by Country (2019-2030)
6.3.3 US & Canada Human Vaccines Administered Orally Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Human Vaccines Administered Orally Market Size by Type
7.1.1 Europe Human Vaccines Administered Orally Sales by Type (2019-2030)
7.1.2 Europe Human Vaccines Administered Orally Revenue by Type (2019-2030)
7.2 Europe Human Vaccines Administered Orally Market Size by Application
7.2.1 Europe Human Vaccines Administered Orally Sales by Application (2019-2030)
7.2.2 Europe Human Vaccines Administered Orally Revenue by Application (2019-2030)
7.3 Europe Human Vaccines Administered Orally Market Size by Country
7.3.1 Europe Human Vaccines Administered Orally Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Human Vaccines Administered Orally Sales by Country (2019-2030)
7.3.3 Europe Human Vaccines Administered Orally Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Human Vaccines Administered Orally Market Size
8.1.1 China Human Vaccines Administered Orally Sales (2019-2030)
8.1.2 China Human Vaccines Administered Orally Revenue (2019-2030)
8.2 China Human Vaccines Administered Orally Market Size by Application
8.2.1 China Human Vaccines Administered Orally Sales by Application (2019-2030)
8.2.2 China Human Vaccines Administered Orally Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Human Vaccines Administered Orally Market Size by Type
9.1.1 Asia Human Vaccines Administered Orally Sales by Type (2019-2030)
9.1.2 Asia Human Vaccines Administered Orally Revenue by Type (2019-2030)
9.2 Asia Human Vaccines Administered Orally Market Size by Application
9.2.1 Asia Human Vaccines Administered Orally Sales by Application (2019-2030)
9.2.2 Asia Human Vaccines Administered Orally Revenue by Application (2019-2030)
9.3 Asia Human Vaccines Administered Orally Sales by Region
9.3.1 Asia Human Vaccines Administered Orally Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Human Vaccines Administered Orally Revenue by Region (2019-2030)
9.3.3 Asia Human Vaccines Administered Orally Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Human Vaccines Administered Orally Market Size by Type
10.1.1 Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Human Vaccines Administered Orally Market Size by Application
10.2.1 Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Country
10.3.1 Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Overview
11.1.3 Merck Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Merck Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck Recent Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Overview
11.2.3 GSK Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 GSK Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Sanofi Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Lanzhou Institute
11.4.1 Lanzhou Institute Company Information
11.4.2 Lanzhou Institute Overview
11.4.3 Lanzhou Institute Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Lanzhou Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Lanzhou Institute Recent Developments
11.5 Serum Institute
11.5.1 Serum Institute Company Information
11.5.2 Serum Institute Overview
11.5.3 Serum Institute Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Serum Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Serum Institute Recent Developments
11.6 Valneva
11.6.1 Valneva Company Information
11.6.2 Valneva Overview
11.6.3 Valneva Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Valneva Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Valneva Recent Developments
11.7 Shanghai United Cell
11.7.1 Shanghai United Cell Company Information
11.7.2 Shanghai United Cell Overview
11.7.3 Shanghai United Cell Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Shanghai United Cell Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shanghai United Cell Recent Developments
11.8 Bibcol
11.8.1 Bibcol Company Information
11.8.2 Bibcol Overview
11.8.3 Bibcol Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Bibcol Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bibcol Recent Developments
11.9 PaxVax
11.9.1 PaxVax Company Information
11.9.2 PaxVax Overview
11.9.3 PaxVax Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 PaxVax Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 PaxVax Recent Developments
11.10 Vabiotech
11.10.1 Vabiotech Company Information
11.10.2 Vabiotech Overview
11.10.3 Vabiotech Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Vabiotech Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Vabiotech Recent Developments
11.11 Tiantan Biological
11.11.1 Tiantan Biological Company Information
11.11.2 Tiantan Biological Overview
11.11.3 Tiantan Biological Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.11.4 Tiantan Biological Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Tiantan Biological Recent Developments
11.12 EuBiologics
11.12.1 EuBiologics Company Information
11.12.2 EuBiologics Overview
11.12.3 EuBiologics Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.12.4 EuBiologics Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 EuBiologics Recent Developments
11.13 Panacea Biotec Ltd
11.13.1 Panacea Biotec Ltd Company Information
11.13.2 Panacea Biotec Ltd Overview
11.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.13.4 Panacea Biotec Ltd Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Panacea Biotec Ltd Recent Developments
11.14 Bio-Med
11.14.1 Bio-Med Company Information
11.14.2 Bio-Med Overview
11.14.3 Bio-Med Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.14.4 Bio-Med Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Bio-Med Recent Developments
11.15 Halfkin Bio-Pharmaceuticals
11.15.1 Halfkin Bio-Pharmaceuticals Company Information
11.15.2 Halfkin Bio-Pharmaceuticals Overview
11.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.15.4 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Halfkin Bio-Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Human Vaccines Administered Orally Industry Chain Analysis
12.2 Human Vaccines Administered Orally Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Vaccines Administered Orally Production Mode & Process
12.4 Human Vaccines Administered Orally Sales and Marketing
12.4.1 Human Vaccines Administered Orally Sales Channels
12.4.2 Human Vaccines Administered Orally Distributors
12.5 Human Vaccines Administered Orally Customers
13 Market Dynamics
13.1 Human Vaccines Administered Orally Industry Trends
13.2 Human Vaccines Administered Orally Market Drivers
13.3 Human Vaccines Administered Orally Market Challenges
13.4 Human Vaccines Administered Orally Market Restraints
14 Key Findings in The Global Human Vaccines Administered Orally Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
1.1 Human Vaccines Administered Orally Product Introduction
1.2 Market by Type
1.2.1 Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Rotavirus Vaccine
1.2.3 Cholera Vaccine
1.2.4 Oral Polio Vaccine
1.3 Market by Application
1.3.1 Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Public
1.3.3 Private
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Vaccines Administered Orally Sales Estimates and Forecasts 2019-2030
2.2 Global Human Vaccines Administered Orally Revenue by Region
2.2.1 Global Human Vaccines Administered Orally Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Human Vaccines Administered Orally Revenue by Region (2019-2024)
2.2.3 Global Human Vaccines Administered Orally Revenue by Region (2025-2030)
2.2.4 Global Human Vaccines Administered Orally Revenue Market Share by Region (2019-2030)
2.3 Global Human Vaccines Administered Orally Sales Estimates and Forecasts 2019-2030
2.4 Global Human Vaccines Administered Orally Sales by Region
2.4.1 Global Human Vaccines Administered Orally Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Human Vaccines Administered Orally Sales by Region (2019-2024)
2.4.3 Global Human Vaccines Administered Orally Sales by Region (2025-2030)
2.4.4 Global Human Vaccines Administered Orally Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Human Vaccines Administered Orally Sales by Manufacturers
3.1.1 Global Human Vaccines Administered Orally Sales by Manufacturers (2019-2024)
3.1.2 Global Human Vaccines Administered Orally Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Vaccines Administered Orally in 2023
3.2 Global Human Vaccines Administered Orally Revenue by Manufacturers
3.2.1 Global Human Vaccines Administered Orally Revenue by Manufacturers (2019-2024)
3.2.2 Global Human Vaccines Administered Orally Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Human Vaccines Administered Orally Revenue in 2023
3.3 Global Key Players of Human Vaccines Administered Orally, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Human Vaccines Administered Orally Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Human Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Human Vaccines Administered Orally, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Human Vaccines Administered Orally, Product Offered and Application
3.8 Global Key Manufacturers of Human Vaccines Administered Orally, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Human Vaccines Administered Orally Sales by Type
4.1.1 Global Human Vaccines Administered Orally Historical Sales by Type (2019-2024)
4.1.2 Global Human Vaccines Administered Orally Forecasted Sales by Type (2025-2030)
4.1.3 Global Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
4.2 Global Human Vaccines Administered Orally Revenue by Type
4.2.1 Global Human Vaccines Administered Orally Historical Revenue by Type (2019-2024)
4.2.2 Global Human Vaccines Administered Orally Forecasted Revenue by Type (2025-2030)
4.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
4.3 Global Human Vaccines Administered Orally Price by Type
4.3.1 Global Human Vaccines Administered Orally Price by Type (2019-2024)
4.3.2 Global Human Vaccines Administered Orally Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Human Vaccines Administered Orally Sales by Application
5.1.1 Global Human Vaccines Administered Orally Historical Sales by Application (2019-2024)
5.1.2 Global Human Vaccines Administered Orally Forecasted Sales by Application (2025-2030)
5.1.3 Global Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
5.2 Global Human Vaccines Administered Orally Revenue by Application
5.2.1 Global Human Vaccines Administered Orally Historical Revenue by Application (2019-2024)
5.2.2 Global Human Vaccines Administered Orally Forecasted Revenue by Application (2025-2030)
5.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
5.3 Global Human Vaccines Administered Orally Price by Application
5.3.1 Global Human Vaccines Administered Orally Price by Application (2019-2024)
5.3.2 Global Human Vaccines Administered Orally Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Human Vaccines Administered Orally Market Size by Type
6.1.1 US & Canada Human Vaccines Administered Orally Sales by Type (2019-2030)
6.1.2 US & Canada Human Vaccines Administered Orally Revenue by Type (2019-2030)
6.2 US & Canada Human Vaccines Administered Orally Market Size by Application
6.2.1 US & Canada Human Vaccines Administered Orally Sales by Application (2019-2030)
6.2.2 US & Canada Human Vaccines Administered Orally Revenue by Application (2019-2030)
6.3 US & Canada Human Vaccines Administered Orally Market Size by Country
6.3.1 US & Canada Human Vaccines Administered Orally Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Human Vaccines Administered Orally Sales by Country (2019-2030)
6.3.3 US & Canada Human Vaccines Administered Orally Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Human Vaccines Administered Orally Market Size by Type
7.1.1 Europe Human Vaccines Administered Orally Sales by Type (2019-2030)
7.1.2 Europe Human Vaccines Administered Orally Revenue by Type (2019-2030)
7.2 Europe Human Vaccines Administered Orally Market Size by Application
7.2.1 Europe Human Vaccines Administered Orally Sales by Application (2019-2030)
7.2.2 Europe Human Vaccines Administered Orally Revenue by Application (2019-2030)
7.3 Europe Human Vaccines Administered Orally Market Size by Country
7.3.1 Europe Human Vaccines Administered Orally Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Human Vaccines Administered Orally Sales by Country (2019-2030)
7.3.3 Europe Human Vaccines Administered Orally Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Human Vaccines Administered Orally Market Size
8.1.1 China Human Vaccines Administered Orally Sales (2019-2030)
8.1.2 China Human Vaccines Administered Orally Revenue (2019-2030)
8.2 China Human Vaccines Administered Orally Market Size by Application
8.2.1 China Human Vaccines Administered Orally Sales by Application (2019-2030)
8.2.2 China Human Vaccines Administered Orally Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Human Vaccines Administered Orally Market Size by Type
9.1.1 Asia Human Vaccines Administered Orally Sales by Type (2019-2030)
9.1.2 Asia Human Vaccines Administered Orally Revenue by Type (2019-2030)
9.2 Asia Human Vaccines Administered Orally Market Size by Application
9.2.1 Asia Human Vaccines Administered Orally Sales by Application (2019-2030)
9.2.2 Asia Human Vaccines Administered Orally Revenue by Application (2019-2030)
9.3 Asia Human Vaccines Administered Orally Sales by Region
9.3.1 Asia Human Vaccines Administered Orally Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Human Vaccines Administered Orally Revenue by Region (2019-2030)
9.3.3 Asia Human Vaccines Administered Orally Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Human Vaccines Administered Orally Market Size by Type
10.1.1 Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Human Vaccines Administered Orally Market Size by Application
10.2.1 Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Country
10.3.1 Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Overview
11.1.3 Merck Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Merck Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck Recent Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Overview
11.2.3 GSK Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 GSK Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Sanofi Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Lanzhou Institute
11.4.1 Lanzhou Institute Company Information
11.4.2 Lanzhou Institute Overview
11.4.3 Lanzhou Institute Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Lanzhou Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Lanzhou Institute Recent Developments
11.5 Serum Institute
11.5.1 Serum Institute Company Information
11.5.2 Serum Institute Overview
11.5.3 Serum Institute Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Serum Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Serum Institute Recent Developments
11.6 Valneva
11.6.1 Valneva Company Information
11.6.2 Valneva Overview
11.6.3 Valneva Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Valneva Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Valneva Recent Developments
11.7 Shanghai United Cell
11.7.1 Shanghai United Cell Company Information
11.7.2 Shanghai United Cell Overview
11.7.3 Shanghai United Cell Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Shanghai United Cell Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shanghai United Cell Recent Developments
11.8 Bibcol
11.8.1 Bibcol Company Information
11.8.2 Bibcol Overview
11.8.3 Bibcol Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Bibcol Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bibcol Recent Developments
11.9 PaxVax
11.9.1 PaxVax Company Information
11.9.2 PaxVax Overview
11.9.3 PaxVax Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 PaxVax Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 PaxVax Recent Developments
11.10 Vabiotech
11.10.1 Vabiotech Company Information
11.10.2 Vabiotech Overview
11.10.3 Vabiotech Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Vabiotech Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Vabiotech Recent Developments
11.11 Tiantan Biological
11.11.1 Tiantan Biological Company Information
11.11.2 Tiantan Biological Overview
11.11.3 Tiantan Biological Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.11.4 Tiantan Biological Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Tiantan Biological Recent Developments
11.12 EuBiologics
11.12.1 EuBiologics Company Information
11.12.2 EuBiologics Overview
11.12.3 EuBiologics Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.12.4 EuBiologics Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 EuBiologics Recent Developments
11.13 Panacea Biotec Ltd
11.13.1 Panacea Biotec Ltd Company Information
11.13.2 Panacea Biotec Ltd Overview
11.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.13.4 Panacea Biotec Ltd Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Panacea Biotec Ltd Recent Developments
11.14 Bio-Med
11.14.1 Bio-Med Company Information
11.14.2 Bio-Med Overview
11.14.3 Bio-Med Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.14.4 Bio-Med Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Bio-Med Recent Developments
11.15 Halfkin Bio-Pharmaceuticals
11.15.1 Halfkin Bio-Pharmaceuticals Company Information
11.15.2 Halfkin Bio-Pharmaceuticals Overview
11.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2019-2024)
11.15.4 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Halfkin Bio-Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Human Vaccines Administered Orally Industry Chain Analysis
12.2 Human Vaccines Administered Orally Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Vaccines Administered Orally Production Mode & Process
12.4 Human Vaccines Administered Orally Sales and Marketing
12.4.1 Human Vaccines Administered Orally Sales Channels
12.4.2 Human Vaccines Administered Orally Distributors
12.5 Human Vaccines Administered Orally Customers
13 Market Dynamics
13.1 Human Vaccines Administered Orally Industry Trends
13.2 Human Vaccines Administered Orally Market Drivers
13.3 Human Vaccines Administered Orally Market Challenges
13.4 Human Vaccines Administered Orally Market Restraints
14 Key Findings in The Global Human Vaccines Administered Orally Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Table 2. Major Manufacturers of Rotavirus Vaccine
Table 3. Major Manufacturers of Cholera Vaccine
Table 4. Major Manufacturers of Oral Polio Vaccine
Table 5. Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Table 6. Global Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 7. Global Human Vaccines Administered Orally Revenue by Region (2019-2024) & (US$ Million)
Table 8. Global Human Vaccines Administered Orally Revenue by Region (2025-2030) & (US$ Million)
Table 9. Global Human Vaccines Administered Orally Revenue Market Share by Region (2019-2024)
Table 10. Global Human Vaccines Administered Orally Revenue Market Share by Region (2025-2030)
Table 11. Global Human Vaccines Administered Orally Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 12. Global Human Vaccines Administered Orally Sales by Region (2019-2024) & (K Units)
Table 13. Global Human Vaccines Administered Orally Sales by Region (2025-2030) & (K Units)
Table 14. Global Human Vaccines Administered Orally Sales Market Share by Region (2019-2024)
Table 15. Global Human Vaccines Administered Orally Sales Market Share by Region (2025-2030)
Table 16. Global Human Vaccines Administered Orally Sales by Manufacturers (2019-2024) & (K Units)
Table 17. Global Human Vaccines Administered Orally Sales Share by Manufacturers (2019-2024)
Table 18. Global Human Vaccines Administered Orally Revenue by Manufacturers (2019-2024) & (US$ Million)
Table 19. Global Human Vaccines Administered Orally Revenue Share by Manufacturers (2019-2024)
Table 20. Global Key Players of Human Vaccines Administered Orally, Industry Ranking, 2022 VS 2023 VS 2024
Table 21. Human Vaccines Administered Orally Price by Manufacturers 2019-2024 (US$/Unit)
Table 22. Global Human Vaccines Administered Orally Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Human Vaccines Administered Orally by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Vaccines Administered Orally as of 2023)
Table 24. Global Key Manufacturers of Human Vaccines Administered Orally, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Human Vaccines Administered Orally, Product Offered and Application
Table 26. Global Key Manufacturers of Human Vaccines Administered Orally, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 29. Global Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 30. Global Human Vaccines Administered Orally Sales Share by Type (2019-2024)
Table 31. Global Human Vaccines Administered Orally Sales Share by Type (2025-2030)
Table 32. Global Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 33. Global Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 34. Global Human Vaccines Administered Orally Revenue Share by Type (2019-2024)
Table 35. Global Human Vaccines Administered Orally Revenue Share by Type (2025-2030)
Table 36. Human Vaccines Administered Orally Price by Type (2019-2024) & (US$/Unit)
Table 37. Global Human Vaccines Administered Orally Price Forecast by Type (2025-2030) & (US$/Unit)
Table 38. Global Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 39. Global Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 40. Global Human Vaccines Administered Orally Sales Share by Application (2019-2024)
Table 41. Global Human Vaccines Administered Orally Sales Share by Application (2025-2030)
Table 42. Global Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 43. Global Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 44. Global Human Vaccines Administered Orally Revenue Share by Application (2019-2024)
Table 45. Global Human Vaccines Administered Orally Revenue Share by Application (2025-2030)
Table 46. Human Vaccines Administered Orally Price by Application (2019-2024) & (US$/Unit)
Table 47. Global Human Vaccines Administered Orally Price Forecast by Application (2025-2030) & (US$/Unit)
Table 48. US & Canada Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 49. US & Canada Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 50. US & Canada Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 51. US & Canada Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 52. US & Canada Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 53. US & Canada Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 54. US & Canada Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 55. US & Canada Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 56. US & Canada Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 57. US & Canada Human Vaccines Administered Orally Revenue by Country (2019-2024) & (US$ Million)
Table 58. US & Canada Human Vaccines Administered Orally Revenue by Country (2025-2030) & (US$ Million)
Table 59. US & Canada Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 60. US & Canada Human Vaccines Administered Orally Sales by Country (2025-2030) & (K Units)
Table 61. Europe Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 62. Europe Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 63. Europe Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 64. Europe Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 65. Europe Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 66. Europe Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 67. Europe Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 68. Europe Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 69. Europe Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 70. Europe Human Vaccines Administered Orally Revenue by Country (2019-2024) & (US$ Million)
Table 71. Europe Human Vaccines Administered Orally Revenue by Country (2025-2030) & (US$ Million)
Table 72. Europe Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 73. Europe Human Vaccines Administered Orally Sales by Country (2025-2030) & (K Units)
Table 74. China Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 75. China Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 76. China Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 77. China Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 78. China Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 79. China Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 80. China Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 81. China Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 82. Asia Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 83. Asia Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 84. Asia Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 85. Asia Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 86. Asia Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 87. Asia Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 88. Asia Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 89. Asia Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 90. Asia Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 91. Asia Human Vaccines Administered Orally Revenue by Region (2019-2024) & (US$ Million)
Table 92. Asia Human Vaccines Administered Orally Revenue by Region (2025-2030) & (US$ Million)
Table 93. Asia Human Vaccines Administered Orally Sales by Region (2019-2024) & (K Units)
Table 94. Asia Human Vaccines Administered Orally Sales by Region (2025-2030) & (K Units)
Table 95. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 97. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 99. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 101. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 103. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 104. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Country (2019-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Country (2025-2030) & (US$ Million)
Table 106. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Country (2025-2030) & (K Units)
Table 108. Merck Company Information
Table 109. Merck Description and Major Businesses
Table 110. Merck Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 111. Merck Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Merck Recent Developments
Table 113. GSK Company Information
Table 114. GSK Description and Major Businesses
Table 115. GSK Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 116. GSK Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. GSK Recent Developments
Table 118. Sanofi Company Information
Table 119. Sanofi Description and Major Businesses
Table 120. Sanofi Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 121. Sanofi Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Sanofi Recent Developments
Table 123. Lanzhou Institute Company Information
Table 124. Lanzhou Institute Description and Major Businesses
Table 125. Lanzhou Institute Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 126. Lanzhou Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Lanzhou Institute Recent Developments
Table 128. Serum Institute Company Information
Table 129. Serum Institute Description and Major Businesses
Table 130. Serum Institute Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 131. Serum Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Serum Institute Recent Developments
Table 133. Valneva Company Information
Table 134. Valneva Description and Major Businesses
Table 135. Valneva Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 136. Valneva Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Valneva Recent Developments
Table 138. Shanghai United Cell Company Information
Table 139. Shanghai United Cell Description and Major Businesses
Table 140. Shanghai United Cell Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 141. Shanghai United Cell Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Shanghai United Cell Recent Developments
Table 143. Bibcol Company Information
Table 144. Bibcol Description and Major Businesses
Table 145. Bibcol Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 146. Bibcol Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Bibcol Recent Developments
Table 148. PaxVax Company Information
Table 149. PaxVax Description and Major Businesses
Table 150. PaxVax Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 151. PaxVax Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. PaxVax Recent Developments
Table 153. Vabiotech Company Information
Table 154. Vabiotech Description and Major Businesses
Table 155. Vabiotech Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 156. Vabiotech Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Vabiotech Recent Developments
Table 158. Tiantan Biological Company Information
Table 159. Tiantan Biological Description and Major Businesses
Table 160. Tiantan Biological Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 161. Tiantan Biological Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. Tiantan Biological Recent Developments
Table 163. EuBiologics Company Information
Table 164. EuBiologics Description and Major Businesses
Table 165. EuBiologics Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 166. EuBiologics Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. EuBiologics Recent Developments
Table 168. Panacea Biotec Ltd Company Information
Table 169. Panacea Biotec Ltd Description and Major Businesses
Table 170. Panacea Biotec Ltd Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 171. Panacea Biotec Ltd Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 172. Panacea Biotec Ltd Recent Developments
Table 173. Bio-Med Company Information
Table 174. Bio-Med Description and Major Businesses
Table 175. Bio-Med Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 176. Bio-Med Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 177. Bio-Med Recent Developments
Table 178. Halfkin Bio-Pharmaceuticals Company Information
Table 179. Halfkin Bio-Pharmaceuticals Description and Major Businesses
Table 180. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 181. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 182. Halfkin Bio-Pharmaceuticals Recent Developments
Table 183. Key Raw Materials Lists
Table 184. Raw Materials Key Suppliers Lists
Table 185. Human Vaccines Administered Orally Distributors List
Table 186. Human Vaccines Administered Orally Customers List
Table 187. Human Vaccines Administered Orally Market Trends
Table 188. Human Vaccines Administered Orally Market Drivers
Table 189. Human Vaccines Administered Orally Market Challenges
Table 190. Human Vaccines Administered Orally Market Restraints
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Vaccines Administered Orally Product Picture
Figure 2. Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Human Vaccines Administered Orally Market Share by Type in 2023 & 2030
Figure 4. Rotavirus Vaccine Product Picture
Figure 5. Cholera Vaccine Product Picture
Figure 6. Oral Polio Vaccine Product Picture
Figure 7. Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 8. Global Human Vaccines Administered Orally Market Share by Application in 2023 & 2030
Figure 9. Public
Figure 10. Private
Figure 11. Human Vaccines Administered Orally Report Years Considered
Figure 12. Global Human Vaccines Administered Orally Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Human Vaccines Administered Orally Revenue 2019-2030 (US$ Million)
Figure 14. Global Human Vaccines Administered Orally Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 15. Global Human Vaccines Administered Orally Revenue Market Share by Region (2019-2030)
Figure 16. Global Human Vaccines Administered Orally Sales 2019-2030 ((K Units)
Figure 17. Global Human Vaccines Administered Orally Sales Market Share by Region (2019-2030)
Figure 18. US & Canada Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 19. US & Canada Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 20. Europe Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 21. Europe Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 22. China Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 23. China Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 24. Asia (excluding China) Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 25. Asia (excluding China) Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 27. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 28. The Human Vaccines Administered Orally Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
Figure 29. The Top 5 and 10 Largest Manufacturers of Human Vaccines Administered Orally in the World: Market Share by Human Vaccines Administered Orally Revenue in 2023
Figure 30. Global Human Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 31. Global Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 32. Global Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 33. Global Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 34. Global Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 35. US & Canada Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 36. US & Canada Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 37. US & Canada Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 38. US & Canada Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 39. US & Canada Human Vaccines Administered Orally Revenue Share by Country (2019-2030)
Figure 40. US & Canada Human Vaccines Administered Orally Sales Share by Country (2019-2030)
Figure 41. U.S. Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 42. Canada Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 43. Europe Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 44. Europe Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 45. Europe Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 46. Europe Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 47. Europe Human Vaccines Administered Orally Revenue Share by Country (2019-2030)
Figure 48. Europe Human Vaccines Administered Orally Sales Share by Country (2019-2030)
Figure 49. Germany Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 50. France Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 51. U.K. Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 52. Italy Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 53. Russia Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 54. China Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 55. China Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 56. China Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 57. China Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 58. Asia Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 59. Asia Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 60. Asia Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 61. Asia Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 62. Asia Human Vaccines Administered Orally Revenue Share by Region (2019-2030)
Figure 63. Asia Human Vaccines Administered Orally Sales Share by Region (2019-2030)
Figure 64. Japan Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 65. South Korea Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 66. China Taiwan Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 67. Southeast Asia Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 68. India Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 70. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 71. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 72. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 73. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue Share by Country (2019-2030)
Figure 74. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales Share by Country (2019-2030)
Figure 75. Brazil Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 76. Mexico Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 77. Turkey Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 78. Israel Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 79. GCC Countries Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 80. Human Vaccines Administered Orally Value Chain
Figure 81. Human Vaccines Administered Orally Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
Table 1. Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Table 2. Major Manufacturers of Rotavirus Vaccine
Table 3. Major Manufacturers of Cholera Vaccine
Table 4. Major Manufacturers of Oral Polio Vaccine
Table 5. Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Table 6. Global Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 7. Global Human Vaccines Administered Orally Revenue by Region (2019-2024) & (US$ Million)
Table 8. Global Human Vaccines Administered Orally Revenue by Region (2025-2030) & (US$ Million)
Table 9. Global Human Vaccines Administered Orally Revenue Market Share by Region (2019-2024)
Table 10. Global Human Vaccines Administered Orally Revenue Market Share by Region (2025-2030)
Table 11. Global Human Vaccines Administered Orally Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 12. Global Human Vaccines Administered Orally Sales by Region (2019-2024) & (K Units)
Table 13. Global Human Vaccines Administered Orally Sales by Region (2025-2030) & (K Units)
Table 14. Global Human Vaccines Administered Orally Sales Market Share by Region (2019-2024)
Table 15. Global Human Vaccines Administered Orally Sales Market Share by Region (2025-2030)
Table 16. Global Human Vaccines Administered Orally Sales by Manufacturers (2019-2024) & (K Units)
Table 17. Global Human Vaccines Administered Orally Sales Share by Manufacturers (2019-2024)
Table 18. Global Human Vaccines Administered Orally Revenue by Manufacturers (2019-2024) & (US$ Million)
Table 19. Global Human Vaccines Administered Orally Revenue Share by Manufacturers (2019-2024)
Table 20. Global Key Players of Human Vaccines Administered Orally, Industry Ranking, 2022 VS 2023 VS 2024
Table 21. Human Vaccines Administered Orally Price by Manufacturers 2019-2024 (US$/Unit)
Table 22. Global Human Vaccines Administered Orally Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Human Vaccines Administered Orally by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Vaccines Administered Orally as of 2023)
Table 24. Global Key Manufacturers of Human Vaccines Administered Orally, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Human Vaccines Administered Orally, Product Offered and Application
Table 26. Global Key Manufacturers of Human Vaccines Administered Orally, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 29. Global Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 30. Global Human Vaccines Administered Orally Sales Share by Type (2019-2024)
Table 31. Global Human Vaccines Administered Orally Sales Share by Type (2025-2030)
Table 32. Global Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 33. Global Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 34. Global Human Vaccines Administered Orally Revenue Share by Type (2019-2024)
Table 35. Global Human Vaccines Administered Orally Revenue Share by Type (2025-2030)
Table 36. Human Vaccines Administered Orally Price by Type (2019-2024) & (US$/Unit)
Table 37. Global Human Vaccines Administered Orally Price Forecast by Type (2025-2030) & (US$/Unit)
Table 38. Global Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 39. Global Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 40. Global Human Vaccines Administered Orally Sales Share by Application (2019-2024)
Table 41. Global Human Vaccines Administered Orally Sales Share by Application (2025-2030)
Table 42. Global Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 43. Global Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 44. Global Human Vaccines Administered Orally Revenue Share by Application (2019-2024)
Table 45. Global Human Vaccines Administered Orally Revenue Share by Application (2025-2030)
Table 46. Human Vaccines Administered Orally Price by Application (2019-2024) & (US$/Unit)
Table 47. Global Human Vaccines Administered Orally Price Forecast by Application (2025-2030) & (US$/Unit)
Table 48. US & Canada Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 49. US & Canada Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 50. US & Canada Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 51. US & Canada Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 52. US & Canada Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 53. US & Canada Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 54. US & Canada Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 55. US & Canada Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 56. US & Canada Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 57. US & Canada Human Vaccines Administered Orally Revenue by Country (2019-2024) & (US$ Million)
Table 58. US & Canada Human Vaccines Administered Orally Revenue by Country (2025-2030) & (US$ Million)
Table 59. US & Canada Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 60. US & Canada Human Vaccines Administered Orally Sales by Country (2025-2030) & (K Units)
Table 61. Europe Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 62. Europe Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 63. Europe Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 64. Europe Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 65. Europe Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 66. Europe Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 67. Europe Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 68. Europe Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 69. Europe Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 70. Europe Human Vaccines Administered Orally Revenue by Country (2019-2024) & (US$ Million)
Table 71. Europe Human Vaccines Administered Orally Revenue by Country (2025-2030) & (US$ Million)
Table 72. Europe Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 73. Europe Human Vaccines Administered Orally Sales by Country (2025-2030) & (K Units)
Table 74. China Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 75. China Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 76. China Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 77. China Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 78. China Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 79. China Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 80. China Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 81. China Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 82. Asia Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 83. Asia Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 84. Asia Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 85. Asia Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 86. Asia Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 87. Asia Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 88. Asia Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 89. Asia Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 90. Asia Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 91. Asia Human Vaccines Administered Orally Revenue by Region (2019-2024) & (US$ Million)
Table 92. Asia Human Vaccines Administered Orally Revenue by Region (2025-2030) & (US$ Million)
Table 93. Asia Human Vaccines Administered Orally Sales by Region (2019-2024) & (K Units)
Table 94. Asia Human Vaccines Administered Orally Sales by Region (2025-2030) & (K Units)
Table 95. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Type (2025-2030) & (K Units)
Table 97. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Type (2019-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Type (2025-2030) & (US$ Million)
Table 99. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Application (2025-2030) & (K Units)
Table 101. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Application (2019-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Application (2025-2030) & (US$ Million)
Table 103. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 104. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Country (2019-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue by Country (2025-2030) & (US$ Million)
Table 106. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales by Country (2025-2030) & (K Units)
Table 108. Merck Company Information
Table 109. Merck Description and Major Businesses
Table 110. Merck Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 111. Merck Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Merck Recent Developments
Table 113. GSK Company Information
Table 114. GSK Description and Major Businesses
Table 115. GSK Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 116. GSK Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. GSK Recent Developments
Table 118. Sanofi Company Information
Table 119. Sanofi Description and Major Businesses
Table 120. Sanofi Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 121. Sanofi Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Sanofi Recent Developments
Table 123. Lanzhou Institute Company Information
Table 124. Lanzhou Institute Description and Major Businesses
Table 125. Lanzhou Institute Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 126. Lanzhou Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Lanzhou Institute Recent Developments
Table 128. Serum Institute Company Information
Table 129. Serum Institute Description and Major Businesses
Table 130. Serum Institute Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 131. Serum Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Serum Institute Recent Developments
Table 133. Valneva Company Information
Table 134. Valneva Description and Major Businesses
Table 135. Valneva Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 136. Valneva Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Valneva Recent Developments
Table 138. Shanghai United Cell Company Information
Table 139. Shanghai United Cell Description and Major Businesses
Table 140. Shanghai United Cell Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 141. Shanghai United Cell Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Shanghai United Cell Recent Developments
Table 143. Bibcol Company Information
Table 144. Bibcol Description and Major Businesses
Table 145. Bibcol Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 146. Bibcol Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Bibcol Recent Developments
Table 148. PaxVax Company Information
Table 149. PaxVax Description and Major Businesses
Table 150. PaxVax Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 151. PaxVax Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. PaxVax Recent Developments
Table 153. Vabiotech Company Information
Table 154. Vabiotech Description and Major Businesses
Table 155. Vabiotech Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 156. Vabiotech Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Vabiotech Recent Developments
Table 158. Tiantan Biological Company Information
Table 159. Tiantan Biological Description and Major Businesses
Table 160. Tiantan Biological Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 161. Tiantan Biological Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. Tiantan Biological Recent Developments
Table 163. EuBiologics Company Information
Table 164. EuBiologics Description and Major Businesses
Table 165. EuBiologics Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 166. EuBiologics Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. EuBiologics Recent Developments
Table 168. Panacea Biotec Ltd Company Information
Table 169. Panacea Biotec Ltd Description and Major Businesses
Table 170. Panacea Biotec Ltd Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 171. Panacea Biotec Ltd Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 172. Panacea Biotec Ltd Recent Developments
Table 173. Bio-Med Company Information
Table 174. Bio-Med Description and Major Businesses
Table 175. Bio-Med Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 176. Bio-Med Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 177. Bio-Med Recent Developments
Table 178. Halfkin Bio-Pharmaceuticals Company Information
Table 179. Halfkin Bio-Pharmaceuticals Description and Major Businesses
Table 180. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 181. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
Table 182. Halfkin Bio-Pharmaceuticals Recent Developments
Table 183. Key Raw Materials Lists
Table 184. Raw Materials Key Suppliers Lists
Table 185. Human Vaccines Administered Orally Distributors List
Table 186. Human Vaccines Administered Orally Customers List
Table 187. Human Vaccines Administered Orally Market Trends
Table 188. Human Vaccines Administered Orally Market Drivers
Table 189. Human Vaccines Administered Orally Market Challenges
Table 190. Human Vaccines Administered Orally Market Restraints
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Vaccines Administered Orally Product Picture
Figure 2. Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Human Vaccines Administered Orally Market Share by Type in 2023 & 2030
Figure 4. Rotavirus Vaccine Product Picture
Figure 5. Cholera Vaccine Product Picture
Figure 6. Oral Polio Vaccine Product Picture
Figure 7. Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 8. Global Human Vaccines Administered Orally Market Share by Application in 2023 & 2030
Figure 9. Public
Figure 10. Private
Figure 11. Human Vaccines Administered Orally Report Years Considered
Figure 12. Global Human Vaccines Administered Orally Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Human Vaccines Administered Orally Revenue 2019-2030 (US$ Million)
Figure 14. Global Human Vaccines Administered Orally Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 15. Global Human Vaccines Administered Orally Revenue Market Share by Region (2019-2030)
Figure 16. Global Human Vaccines Administered Orally Sales 2019-2030 ((K Units)
Figure 17. Global Human Vaccines Administered Orally Sales Market Share by Region (2019-2030)
Figure 18. US & Canada Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 19. US & Canada Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 20. Europe Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 21. Europe Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 22. China Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 23. China Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 24. Asia (excluding China) Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 25. Asia (excluding China) Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales YoY (2019-2030) & (K Units)
Figure 27. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue YoY (2019-2030) & (US$ Million)
Figure 28. The Human Vaccines Administered Orally Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
Figure 29. The Top 5 and 10 Largest Manufacturers of Human Vaccines Administered Orally in the World: Market Share by Human Vaccines Administered Orally Revenue in 2023
Figure 30. Global Human Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 31. Global Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 32. Global Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 33. Global Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 34. Global Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 35. US & Canada Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 36. US & Canada Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 37. US & Canada Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 38. US & Canada Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 39. US & Canada Human Vaccines Administered Orally Revenue Share by Country (2019-2030)
Figure 40. US & Canada Human Vaccines Administered Orally Sales Share by Country (2019-2030)
Figure 41. U.S. Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 42. Canada Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 43. Europe Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 44. Europe Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 45. Europe Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 46. Europe Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 47. Europe Human Vaccines Administered Orally Revenue Share by Country (2019-2030)
Figure 48. Europe Human Vaccines Administered Orally Sales Share by Country (2019-2030)
Figure 49. Germany Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 50. France Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 51. U.K. Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 52. Italy Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 53. Russia Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 54. China Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 55. China Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 56. China Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 57. China Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 58. Asia Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 59. Asia Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 60. Asia Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 61. Asia Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 62. Asia Human Vaccines Administered Orally Revenue Share by Region (2019-2030)
Figure 63. Asia Human Vaccines Administered Orally Sales Share by Region (2019-2030)
Figure 64. Japan Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 65. South Korea Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 66. China Taiwan Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 67. Southeast Asia Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 68. India Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
Figure 70. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
Figure 71. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
Figure 72. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
Figure 73. Middle East, Africa and Latin America Human Vaccines Administered Orally Revenue Share by Country (2019-2030)
Figure 74. Middle East, Africa and Latin America Human Vaccines Administered Orally Sales Share by Country (2019-2030)
Figure 75. Brazil Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 76. Mexico Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 77. Turkey Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 78. Israel Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 79. GCC Countries Human Vaccines Administered Orally Revenue (2019-2030) & (US$ Million)
Figure 80. Human Vaccines Administered Orally Value Chain
Figure 81. Human Vaccines Administered Orally Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232